NEW YORK, Aug. 5 (GenomeWeb News) - Transgenomic today reported decreased second-quarter revenues amid widened net losses.
The Omaha, Neb. company had revenues of $8.5 million for the quarter, compared to $9.4 million for the same period last year.
Losses totalled $4.7 million, compared to $4.0 million for the year-ago quarter.
R&D expenses decreased also, to $2.4 million, from $3.0 million in the same period last year.
As of June 30, the company had cash, cash equivalents, and short-term investments of $3.0 million.